
Kathy Oubre Previews Biosimilar Discussion at the 2021 Community Oncology Alliance
Kathy Oubre, MS, chief operating officer, Pontchartrain Cancer Center, explores US adoption of biosimilars ahead of her panel discussion at the 2021 Community Oncology Conference, as well as what sessions she’s looking forward to attending.
Kathy Oubre, MS, is the chief operating officer at Pontchartrain Cancer Center.
Transcript
For the
Oubre: So, US adoption of biosimilars continues to gain traction. According to a recent analysis by Ronny Gal, senior analyst with Bernstein and a presenter at COA this year, in the latter part of 2020, the market reached an annualized savings of approximately $7 billion for the overall US health care system.
In addition, a recent NCCN [National Comprehensive Cancer Network] poster presented showed
These market shifts are likely a combination of patient acceptance, physician confidence, and a growing demand from patients, physicians, and employer groups for payers to include biosimilars on their formularies.
A recent
What sessions or topics at this year’s conference will you be interested to learn more on?
Oubre: I'm most interested to hear Ronny Gal, the senior analyst from Bernstein, who will discuss the
So, on the pharmacy side, the PBM [pharmacy benefit manager] and payer update will be fascinating. And we will have an amazing panel with John Levitt from Frier Levitt, our own Ted Okon, Rich Ingram, MD, and Stuart Genschaw. This session will be sure to highlight the games and tricks that PBMs and insurers play.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.